另外，考虑到透析治疗所需的高昂费用，即每年至少需要投入10万元，长期下来，整个透析治疗过程的费用将高达惊人的100万元。而相比之下，选择使用耐赋康不仅能够获得更为显著的治疗效果，还能在很大程度上减轻患者及其家庭的经济负担。因此，耐赋康的上市无疑为患者提供了一种既高效又经济的治疗选择，实现了医疗效果与经济效益的完美结合。With the successful dispensing of Nifukang's first prescription, the cost of its treatment attracted widespread attention in the market.
The Zhitong Finance App learned that with the successful issuance of Nifukang's first prescription, its treatment costs have attracted widespread attention in the market. According to an authoritative source, Nifukang's pricing strategy is very friendly. You can get one bottle for only 18,600 yuan, and if you buy four bottles, you will also get an additional bottle, reducing the actual price paid for each bottle to 14,900 yuan, thus significantly increasing its cost performance advantage. What is particularly remarkable is that each treatment cycle requires only 9.5 bottles of Nafucan, and an additional 2 bottles will be received during this period, which undoubtedly brings more real benefits and benefits to patients.
At the same time, compared to the high price of 100,000 yuan/bottle in the US market, Nifukang's domestic pricing can be called “affordable”, which is only equivalent to a 15% discount, fully demonstrating its strong competitiveness in terms of price. Behind this competitiveness is Nifukang's outstanding performance in treating IgA nephropathy. According to reports, Nifukang can effectively delay the time for patients to enter the dialysis or kidney transplant stage, and its remarkable curative effects can even benefit patients for as long as 12.8 years. Taking Chinese patients as an example, their disease progressed faster. The phase III clinical study showed that in two years, EGFR in the control group that only used RAS inhibitors decreased by 21 ml/min, while in the treatment group that used only defucan decreased by 7 ml/min, a decrease of 66%, so the sooner you use Tolerant Health, the more remaining kidney function was saved, and the risk of progression to kidney failure was lower.
Also, considering the high cost of dialysis treatment, that is, at least 100,000 yuan per year, the cost of the entire dialysis treatment process will be as high as 1 million yuan in the long run. In contrast, choosing to use Nifukang can not only obtain more significant treatment results, but also reduce the financial burden on patients and their families to a large extent. Therefore, the launch of Nifukang undoubtedly provides patients with an efficient and economical treatment option, achieving a perfect combination of medical effects and economic benefits.
